Global Life Science Business Partnering (GLSBP)

Highlights of February 2023:

India's Biocon raises US$129 Million from Kotak to fund biosimilars deal.
Marengo Asia Healthcare acquires 100% stake in W Pratiksha Hospital.
Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine.
Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma.
Akums, Lyrus Life Sciences collaborate for patented technologies and formulation.
MediBuddy acquires vHealth by Aetna.
Olympus to buy Korean GI stent company, Taewoong Medical for US$370 Million.
Cue Biopharma enters collaboration and option agreement with Ono Pharma for CUE-401 to treat autoimmune & inflammatory diseases.
Destiny Pharma out-licenses NTCD-M3 to Sebela.
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate.
Teijin and Axcelead to form drug discovery research JV.
Capricor now partners with Nippon Shinyaku for CAP-1002 in Japan.
Advanz Pharma inks deal with Alvotech to commercialize Xolair biosimilar.

Updates at Aagami:

Aagami celebrating 20 years in business. As a part of its 20^th Anniversary year, Aagami will offer special benefits and discounts to its clients up until 31^st March 2023.
Aagami to attend DCAT 2023 in New York City (March 20–23). Meeting calendar is filling fast with only few slots open. If you would like to meet, please send your request soon.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Investment:

Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.
Lidocaine 10% Topical Patch; NDA approval expected in September 2023. (Licensing for US available). Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia).
Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. An unmet need for treating Bacterial Dysentery. Seeking funding/licensing/co-development partnerships.

For Acquisition:

Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. for Next-generation biologics and substantial returns.